Availability of more nonprescription naloxone nasal sprays could bring down costs, agency says
— Availability of more nonprescription naloxone nasal sprays could bring down costs, agency says
by Shannon Firth, Enterprise & Investigative Writer, MedPage Today
June 16, 2026
• 2 min read
The FDA approved another opioid overdose reversal product for over-the-counter (OTC) use, the agency announced on Tuesday.
Federal officials cite decline in opioid-related deaths but warn progress is fragile
An experimental fentanyl vaccine showed promise in an early-stage trial
Super-potent synthetic opioids called nitazenes are spreading across the U.S.
Antidepressants could be used for pain relief instead of opioids
ARMR Sciences Achieves Major Milestone Toward Overdose Protection, Produces First-Ever Anti-Fentanyl Immune Response in Humans
Drug shortages lasting longer; discontinuations at highest level since 2019
Over-the-counter sales for the overdose reversal drug naloxone have been low, a trend researchers reported is likely due to its…
Sales of the overdose reversal medication naloxone increased after it was made available to the public without a prescription but…
Scienture expands Rezenopy access through a major health plan ahead of launch, adding coverage for more than 100 million lives.
About 70,000 Americans died of drug overdoses last year — about 14% fewer than the previous year, according to preliminary…
A new study by emergency medicine researchers at UC Davis Health set out to assess the effects of naloxone administration by…
Victoria's Voice Foundation Marks National Naloxone Awareness Day on June 6
